Abstract
A new sensitive and fast quantitative analytical method for the simultaneous determination of clopidogrel, its main metabolite clopidogrel carboxylic acid, and the newly described acyl glucuronide metabolite, in human plasma samples, is presented. The analytical procedures (plasma storage, handling, and extract storage in the autosampler) were optimized in order to avoid back-conversion; a known drawback in measurements of clopidogrel. Clopidogrel acyl glucuronide was confirmed as a major source of back-conversion to the parent drug in the presence of methanol, and thorough stability experiments were carried out to find the most appropriate conditions for an accurate analysis of clopidogrel and the two metabolites. The method was validated by assessing selectivity, sensitivity, linearity, accuracy, and precision for all three analytes, in accordance to Food and Drug Administration guidelines. Spiked quality controls in plasma as well as incurred samples were used to verify back-conversion in the selected conditions, with results meeting European Medicines Agency acceptance criteria (concentrations within 80–120% of the first reading). The method was then applied to a pharmacokinetic study, and for the first time, a pharmacokinetic curve of clopidogrel acyl glucuronide in human plasma is presented. The concentrations ranged up to 1,048.684 ng/mL, with a mean of 470.268 ng/mL, while clopidogrel had a mean C max of 1.348 ng/mL; these orders of magnitude show how much the back-conversion of this metabolite may influence clopidogrel quantification if it is not properly controlled.
References
Lagorce P, Perez Y, Ortiz J, Necciari J, Bressolle F (1998) J Chromatrogr B Biomed Sci Appl 720:107–117
Bahrami G, Mohammadi B, Sisakhtnezhad S (2008) J Chromatrogr B Biomed Sci Appl 864:168–172
Mitakos A, Panderi I (2004) Anal Chim Acta 505:107–114
Savi P, Pereillo JM, Uzabiaga F, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM (2000) Thromb Haemost 84:891–896
Pereillo JM, Maftouh M, Andrieu A, Uzabiaga M, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C (2002) Drug Metab Dispos 30:1288–1295
Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schömig A, Schömig E (2004) Thromb Haemost 92:311–316
Lainesse A, Ozalp Y, Wong H, Alpan RS (2004) Arzneim Forsch/Drug Res 54:600–604
Nirogi RVS, Kandikere VN, Mudingonda C (2006) Arzneim Forsch/Drug Res 56:735–739
Robinson A, Hillis J, Neal C, Leary AC (2007) J Chromatogr B Biomed Sci Appl 848:344–354
Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A (2008) J Pharm Biomed Anal 48:1219–1224
Silvestro L, Gheorghe MC, Tarcomnicu I, Savu S, Savu R, Iordachescu A, Dulea C (2010) J Chromatrogr B Biomed Sci Appl 878:3134–3142
Yerino P, Toren P, Ogilvie B, Parkinson A (2006) Poster presentation. 14th North American Regional ISSX Meeting. Available at http://mms.technologynetworks.net/posters/0324.pdf. Accessed 04 Feb 2011
Havard G, Coulombe ME, Lachance S, Lévesque A, Massé R (2009) AAPS Journal 11 (S2). Annual meeting. Available at http://www.aapsj.org/abstracts/AM_2009/AAPS2009-003196.pdf
Garofolo F (2009) Impact of unstable metabolites during drug quantification and specific evaluation of acyl glucuronide metabolites in bioanalysis. Lecture, AAPS Symposium, Nov 2009
Food and Drug Administration (2001) Guidance for industry/bioanalytical method validation. USFDA, Rockville
Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, PShah VP, Skelly JP, Swann PG, Weiner R (2007) AAPS J 9(1):E30–E42
Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Anal Chem 75:3019–3030
Kelly T, Gray TR, Huestis MA (2008) J Chromatrogr B Biomed Sci Appl 867:194–204
Khan S, Teitz DS, Jemal M (1998) Anal Chem 70:1622–1628
Shipkova M, Armstrong VW, Oellerich M, Wieland E (2003) Ther Drug Monit 25:1–16
Ferreirós N, Dresen S, Alonso RM, Weinmann W (2007) J Chromatogr B Biomed Sci Appl 855:134–138
Jemal M, Ouyang Z, Xia YQ (2010) Biomed Chromatogr 24:2–19
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) (2009) Guideline on validation of bioanalytical methods. Doc. Ref. EMEA/CHMP/EWP/192217/2009, Nov 2009
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Silvestro, L., Gheorghe, M., Iordachescu, A. et al. Development and validation of an HPLC–MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. Anal Bioanal Chem 401, 1023–1034 (2011). https://doi.org/10.1007/s00216-011-5147-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-011-5147-4